Radiopharm Theranostics (RAD) Stock Price, News & Analysis

Company Overview

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $60.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:RAD
• CIK: N/A
• Web: www.riteaid.com
• Phone: 17177612633
• Fax: N/A
• Employees: 2,021
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.95 million
• Net Margins: -4,896.45%
• Pretax Margin: N/A
• Return on Equity: -183.16%
• Return on Assets: -30.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.30
• Quick Ratio: 3.43

Sales & Book Value

• Annual Sales: $1.96 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,170,000,000
• Free Float: N/A
• Market Cap: $60.78 million
• Optionable: Not Optionable
• Beta: 0.82